Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
复制标题
DOI：
10.3389/fimmu.2021.643310
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Khakoo SI
中科院分区：
文献类型：
--
作者：
Bozward AG;Warricker F;Oo YH;Khakoo SI
尽管免疫治疗取得了重大进展，但肝细胞癌（HCC）仍然是一个具有挑战性的目标。自然杀伤（NK）细胞是抗HCC免疫应答的关键组分，其可以作为主要靶标、肿瘤微环境的调节剂并与肿瘤抗原特异性效应CD 8细胞同步用于肿瘤清除，以获得免疫益处。调节性T细胞通过多种抑制机制塑造来自效应T细胞的抗肿瘤应答。未来的研究需要解决新的NK细胞靶向免疫治疗的发展和抑制肝癌中Treg的频率和功能。我们现在已经进入了使用基于检查点抑制剂（CPI）的策略进行抗癌治疗的新时代。将GMP-NK细胞免疫疗法与CPI结合以提高NK细胞的频率，CPI靶向NK和CD 8 T细胞以释放共抑制受体并提高HCC的细胞抗肿瘤免疫力，将是HCC治疗中有吸引力的治疗选择。这些治疗方法现在应该通过应用基因组学，蛋白质组学和代谢组学方法来理解HCC的微环境，再加上治疗前和治疗期间外周血和HCC组织的深度免疫分析，将提供急需的个性化医学方法，以改善HCC患者的临床结局。
Despite major advances in immunotherapy, hepatocellular carcinoma (HCC) remains a challenging target. Natural Killer (NK) cells are crucial components of the anti-HCC immune response, which can be manipulated for immunotherapeutic benefit as primary targets, modulators of the tumour microenvironment and in synchronising with tumour antigen specific effector CD8 cells for tumour clearance. Regulatory T cells shape the anti-tumour response from effector T cells via multiple suppressive mechanisms. Future research is needed to address the development of novel NK cell-targeted immunotherapy and on restraining Treg frequency and function in HCC. We have now entered a new era of anti-cancer treatment using checkpoint inhibitor (CPI)-based strategies. Combining GMP-NK cell immunotherapy to enhance the frequency of NK cells with CPI targeting both NK and CD8 T cells to release co-inhibitory receptors and enhance the cells anti-tumour immunity of HCC would be an attractive therapeutic option in the treatment of HCC. These therapeutic approaches should now be complemented by the application of genomic, proteomic and metabolomic approaches to understanding the microenvironment of HCC which, together with deep immune profiling of peripheral blood and HCC tissue before and during treatment, will provide the much-needed personalised medicine approach required to improve clinical outcomes for patients with HCC.
登录
查看更多内容
影响因子：
4.4
作者：
Carrega, Paolo;Bonaccorsi, Irene;Ferlazzo, Guido
通讯作者：
Ferlazzo, Guido
影响因子：
17.1
作者：
Balmer, Maria L.;Slack, Emma;Macpherson, Andrew J.
通讯作者：
Macpherson, Andrew J.
影响因子：
15.9
作者：
Bowen, DG;Zen, M;Bertolino, P
通讯作者：
Bertolino, P
影响因子：
13.5
作者：
Calderaro, Julien;Rousseau, Benoit;Pawlotsky, Jean-Michel
通讯作者：
Pawlotsky, Jean-Michel
影响因子：
7.2
作者：
Cariani, Elisabetta;Pilli, Massimo;Missale, Gabriele
通讯作者：
Missale, Gabriele